BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38215747)

  • 21. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
    Tomar VS; Patil V; Somasundaram K
    Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioblastoma Recurrence and the Role of O
    Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
    JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
    Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
    J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
    Jin L; Kiang KM; Cheng SY; Leung GK
    Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
    Wang D; Berglund A; Kenchappa RS; Forsyth PA; Mulé JJ; Etame AB
    Sci Rep; 2016 Feb; 6():21710. PubMed ID: 26888114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
    Yao YM; Donoho GP; Iversen PW; Zhang Y; Van Horn RD; Forest A; Novosiadly RD; Webster YW; Ebert P; Bray S; Ting JC; Aggarwal A; Henry JR; Tiu RV; Plowman GD; Peng SB
    Clin Cancer Res; 2017 Sep; 23(18):5547-5560. PubMed ID: 28611205
    [No Abstract]   [Full Text] [Related]  

  • 31. RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
    Chen Y; Mu Y; Guan Q; Li C; Zhang Y; Xu Y; Zhou C; Guo Y; Ma Y; Zhao M; Ji G; Liu P; Sun D; Sun H; Wu N; Jin Y
    Cell Death Dis; 2023 Nov; 14(11):757. PubMed ID: 37985768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
    Ma Z; Cai S; Xiong Q; Liu W; Xia H; Zhu Z; Huang Z; Yan X; Wang Q
    Apoptosis; 2022 Feb; 27(1-2):80-89. PubMed ID: 35037107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
    Vaubel RA; Tian S; Remonde D; Schroeder MA; Mladek AC; Kitange GJ; Caron A; Kollmeyer TM; Grove R; Peng S; Carlson BL; Ma DJ; Sarkar G; Evers L; Decker PA; Yan H; Dhruv HD; Berens ME; Wang Q; Marin BM; Klee EW; Califano A; LaChance DH; Eckel-Passow JE; Verhaak RG; Sulman EP; Burns TC; Meyer FB; O'Neill BP; Tran NL; Giannini C; Jenkins RB; Parney IF; Sarkaria JN
    Clin Cancer Res; 2020 Mar; 26(5):1094-1104. PubMed ID: 31852831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
    Shi J; Dong X; Han W; Zhou P; Liu L; Wang H; Jiang Q; Li H; Cheng S; Li S; Yuan J; Qian Z; Dong J
    Anticancer Drugs; 2022 Jan; 33(1):e381-e388. PubMed ID: 34419956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
    Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
    Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
    Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
    Hasan T; Caragher SP; Shireman JM; Park CH; Atashi F; Baisiwala S; Lee G; Guo D; Wang JY; Dey M; Wu M; Lesniak MS; Horbinski CM; James CD; Ahmed AU
    Cell Death Dis; 2019 Mar; 10(4):292. PubMed ID: 30926789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    Yu J; Gao G; Wei X; Wang Y
    BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.